This is the latest sortie in the war between over- and under-treatment of osteoporosis.
In this video, Steven R. Goldstein, MD, professor of obstetrics and gynecology at NYU, discusses new research he presented in October at the 25th annual North American Menopause Society meeting.
Menopause will be unique for each woman, and a physician-patient partnership is a must if women want effective menopause management.
Osteoporosis isn't a disease of older women; it's a disease of all women, incubating in even our youngest patients.
Look no further: The North American Menopause Society has issued recommendations that offer the latest information for managing a woman's health through menopause.
Bisphosphonates offer women no protection against breast cancer but do help prevent fractures related to osteoporosis.
The FDA has approved Duavee, the first medication to combine estrogen with bazedoxifene, for the treatment of hot flashes and the prevention of osteoporosis after menopause.
Women who experience early menopause are almost twice as likely to have osteoporosis and are at greater risk for fracture and death than women who experience menopause later in life, according to results of a 34-year study conducted in Sweden.
Decreases in bone mineral density and an increased risk of arthritis may be linked to bilateral oophorectomy, according to new research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
Women with breast cancer have a new ally in their fight, as researchers now believe zoledronic acid will help prevent bone loss associated with adjuvant aromatase inhibitor therapy. The latest results from the Z-FAST trial were published in Cancer by Dr Adam M. Brufsky, professor of medicine at the University of Pittsburgh School of Medicine and associate director of clinical investigation for the University of Pittsburgh Cancer Institute, and colleagues.